Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats

Cancer Prevention Research

Volumn 4, Issue 11, 2011, Pages 1895-1902

  Suh, Nanjoo ^a,d   Reddy, Bandaru S ^a   DeCastro, Andrew ^a   Paul, Shiby ^a   Lee, Hong Jin ^a   Smolarek, Amanda K ^a   So, Jae Young ^a   Simi, Barbara ^a   Wang, Chung Xiou ^a   Janakiram, Naveena B ^b   Steele, Vernon ^c   Rao, Chinthalapally V ^b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZOXYMETHANE; BETA CATENIN; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 4; NAPROXEN; SULINDAC; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER TISSUE; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; TISSUE LEVEL; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZOXYMETHANE; BETA CATENIN; CARCINOGENS; COLONIC NEOPLASMS; CYCLIN D1; EIF-2 KINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANOIC ACIDS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-4; MALE; NAPROXEN; NITRIC OXIDE SYNTHASE TYPE II; PYRROLES; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; SULINDAC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81555210871     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0222     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18: 1688-94.
4. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009;10: 211-9.
5. Kawamori T, Takahashi M, Watanabe K, Ohta T, Nakatsugi S, Sugimura T, et al. Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Cancer Lett 2000;148:33-7. (Pubitemid 30012126)
6. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 2005;258: 115-23. (Pubitemid 41025968)
7. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165-70. (Pubitemid 34074001)
8. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004;95:475-80. (Pubitemid 38832695)
9. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase- 2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-62. (Pubitemid 26113767)
10. Ohta T, Takahashi M, Ochiai A. Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers. Cancer Lett 2006;239:246-53. (Pubitemid 43974868)
11. Takahashi M, Mutoh M, Shoji Y, Sato H, Kamanaka Y, Naka M, et al. Suppressive effect of an inducible nitric oxide inhibitor, ONO-1714, on AOM-induced rat colon carcinogenesis. Nitric Oxide 2006; 14:130-6. (Pubitemid 43165878)
12. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12. (Pubitemid 28087398)
13. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21: 155-64. (Pubitemid 34655036)
14. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-56. (Pubitemid 33585926)
15. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5:1530-8. (Pubitemid 44070490)
16. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats. Cancer Res 2006;66:4542-6.
17. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthaseselective inhibitor. Carcinogenesis 1999;20:641-4. (Pubitemid 29151301)
18. Chen T, Hwang H, Rose ME, Nines RG, Stoner GD. Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamineinduced rat esophageal tumorigenesis: down-regulation of cyclooxygenase- 2, inducible nitric oxide synthase, and c-Jun. Cancer Res 2006;66:2853-9.
19. Reddy BS, Hirose Y, Cohen LA, Simi B, Cooma I, Rao CV. Preventive potential of wheat bran fractions against experimental colon carcinogenesis: implications for human colon cancer prevention. Cancer Res 2000;60:4792-7.
20. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-72.
21. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-19. (Pubitemid 39345400)
22. Luceri C, Caderni G, Sanna A, Dolara P. Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane- induced f344 rat colon tumors. J Nutr 2002;132:1376-9. (Pubitemid 34606479)
23. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999;59:3387-91. (Pubitemid 29334497)
24. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006;66:7370-7. (Pubitemid 44197721)
25. Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, et al. Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res 2009;2:951-6.
26. Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435-8. (Pubitemid 26242647)
27. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57:1301-5. (Pubitemid 27152555)
28. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the {beta}-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000;21:1117-20. (Pubitemid 30389335)
29. Kaiser S, Park Y-K, Franklin J, Halberg R, Yu M, Jessen W, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131.
30. Wang QS, Papanikolaou A, Sabourin CL, Rosenberg DW. Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane- induced mouse colon tumorigenesis. Carcinogenesis 1998; 19:2001-6. (Pubitemid 28521944)
31. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90. (Pubitemid 27136715)
32. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74. (Pubitemid 26071834)
33. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24.
34. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 1997;57:169-75. (Pubitemid 27020348)
35. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6. (Pubitemid 29180374)
36. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24. (Pubitemid 36627817)
37. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98. (Pubitemid 351589714)
38. He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12. (Pubitemid 28425575)
39. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40. (Pubitemid 43361545)
40. Suh N, Paul S, Hao X, Simi B, Xiao H, Rimando AM, et al. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin Cancer Res 2007;13:350-5. (Pubitemid 46121889)
41. Feagins LA, Souza RF, Spechler SJCarcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009;6:297-305.
42. Fantini MC, Pallone F, Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008;9:375-80. (Pubitemid 352025211)
43. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6. (Pubitemid 44050137)
44. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008;659:15-30.
45. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539.
46. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-7. (Pubitemid 38314410)
47. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009;220:292-6.
48. Reddy BS. Strategies for colon cancer prevention: combination of chemopreventive agents. Subcell Biochem 2007;42:213-25.
49. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95. (Pubitemid 44315981)